Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Nektar Therapeutics (NKTR) PT Raised to $20 at Oppenheimer
November 7, 2019 10:24 AM ESTOppenheimer analyst Jay Olson raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $20.00 (from $18.00) while maintaining a Perform rating.
The analyst commented, "Nektar reported 3Q19 financial results, revised 2019 guidance, and provided pipeline updates including multiple catalysts. While NKTR has several promising... More
Nektar Therapeutics (NKTR) PT Lowered to $40 at Cowen
November 7, 2019 8:26 AM ESTCowen lowered its price target on Nektar Therapeutics (NASDAQ: NKTR) to $40.00 (from $43.00) while maintaining a Outperform rating.... More
Nektar Therapeutics (NKTR) PT Lowered to $35 at Piper Jaffray
November 7, 2019 6:57 AM ESTPiper Jaffray analyst Tyler Van Buren lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) to $35.00 (from $50.00) while maintaining a Overweight rating.... More
